As of November 6, 2026, INmune Bio Inc. is a publicly traded company (Nasdaq: INMB); its largest reported holder is Highbridge, with 5.2% on Schedule 13G/A of August 14, 2025. The largest insider holding is Lowdell Mark William, the chief scientific officer, with 1,518,017 shares (4.9% of shares outstanding), per Form 4 of July 7, 2026 (Schedule 13G/A, August 14, 2025).
Is this your company?
About to sign with, pay or invest in INmune Bio Inc.? See the free Snapshot first.
Free to see. No signup.
Is INmune Bio Inc. a real, registered company?
- INmune Bio Inc. files with the SEC under CIK 1711754 (its SEC filings).
- Its shares are listed under the ticker INMB on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in Boca Raton, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under INmune Bio Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Highbridge (filed 2025-08-14).
Who are INmune Bio Inc.'s owners and officers?
INmune Bio Inc.: incorporated in Nevada; business address in Boca Raton, Florida; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2025-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2025-08-14 | Cvi Investments, Inc. | 4.9% |
| Schedule 13G/A, 2025-08-14 | Kupperman Harris | 3.4% |
| Schedule 13G/A, 2025-08-14 | Highbridge Capital Management, LLC | 5.2% |
| Schedule 13G, 2025-07-02 | Cvi Investments, Inc. | 5.5% |
Questions about who owns INmune Bio Inc.
Who owns INmune Bio Inc.?
On this page, one holder's latest ownership filing reports 5% or more of INmune Bio Inc.: Highbridge Capital Management, LLC (5.2%, Schedule 13G/A, filed 2025-08-14).
When did Highbridge Capital Management, LLC buy into INmune Bio Inc.?
The filings give report dates, not purchase dates. The earliest filing from Highbridge Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 5.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on INmune Bio Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on INmune Bio Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on INmune Bio Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own INmune Bio Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief scientific officer: 1,518,017 shares (4.9% of shares outstanding) (Form 4, 2026-07-07).
- , the chief executive and a director: 1,294,883 shares (4.2% of shares outstanding) (Form 4, 2026-07-07).
- , a director: 86,404 shares (0.28% of shares outstanding) (Form 4, 2026-07-07).
Shares outstanding: 30,959,079 as of 2026-11-05, from the company's latest SEC cover page.
How much has INmune Bio Inc. raised?
No fundraising or offering filing from INmune Bio Inc. is on file with us.
Keep reading
More on INmune Bio Inc. and the records around it.
INmune Bio Inc. elsewhere on the record
- 5%+ stake filings Aug 2025
Companies that share a holder
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/inmune-bio